阿维鲁单抗联合他拉唑帕利治疗晚期实体瘤患者:JAVELIN PARP Medley 非随机对照试验
这项1b/2期篮式非随机对照试验共治疗223例晚期实体瘤患者,评估阿维鲁单抗联合他拉唑帕利。2期推荐剂量为阿维鲁单抗800 mg每2周联合他拉唑帕利1 mg每日一次。三阴性乳腺癌客观缓解率18.2%,激素受体阳性/ERBB2阴性/DDR阳性乳腺癌34.8%,铂敏感BRCA1/2突变卵巢癌63.6%,BRCA1/2突变肿瘤缓解更常见。
要点
- 2期推荐剂量为阿维鲁单抗800 mg每2周联合他拉唑帕利1 mg每日一次。
- 三阴性乳腺癌客观缓解率18.2%(95% CI 5.2%-40.3%)。
- 铂敏感BRCA1/2突变卵巢癌客观缓解率63.6%(95% CI 30.8%-89.1%)。
核心结论
- 该非随机对照试验发现,阿维鲁单抗联合他拉唑帕利的客观缓解率与PARP抑制剂或免疫检查点抑制剂单药治疗相当。
- 三阴性乳腺癌、激素受体阳性/ERBB2阴性/DDR阳性乳腺癌及BRCA1/2突变卵巢癌中观察到的持久缓解值得在随机临床试验中进一步研究。
- 这些数据强调在未来免疫检查点抑制剂与PARP抑制剂联合研究中前瞻性选择患者的重要性。
研究设计与样本
- 这是一项1b期和2期篮式非随机对照试验,纳入晚期实体瘤患者。
- 队列包括非小细胞肺癌、DDR阳性非小细胞肺癌、三阴性乳腺癌、激素受体阳性/ERBB2阴性/DDR阳性乳腺癌、复发性铂敏感卵巢癌、复发性铂敏感BRCA1/2突变卵巢癌、尿路上皮癌、转移性去势抵抗性前列腺癌、DDR阳性转移性去势抵抗性前列腺癌及BRCA1/2或ATM突变实体瘤。
- 共治疗223例患者,包括1b期12例和2期211例;平均(标准差)年龄63.2(11.0)岁,男性117例(52.5%)。
- 数据分析时间为2021年6月17日至2021年8月6日。
- 1b期主要终点为剂量限制性毒性,2期主要终点为客观缓解率。
主要发现
- 2期推荐剂量为阿维鲁单抗800 mg每2周联合他拉唑帕利1 mg每日一次。
- 2期三阴性乳腺癌客观缓解率为18.2%(95% CI 5.2%-40.3%)。
- 2期激素受体阳性/ERBB2阴性/DDR阳性乳腺癌客观缓解率为34.8%(95% CI 16.4%-57.3%)。
- 2期铂敏感BRCA1/2突变卵巢癌客观缓解率为63.6%(95% CI 30.8%-89.1%)。
- BRCA1/2突变肿瘤中缓解更常见;三阴性乳腺癌中位缓解持续时间11.1个月(范围3.4-20.4),激素受体阳性/ERBB2阴性/DDR阳性乳腺癌15.7个月(范围3.9至≥20.6),BRCA1/2突变卵巢癌未达到(范围5.6至≥18.4)。
关键数值与推荐
- 最常见≥3级治疗相关不良事件为贫血75例(33.6%)、血小板减少48例(21.5%)和中性粒细胞减少31例(13.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出三阴性乳腺癌、激素受体阳性/ERBB2阴性/DDR阳性乳腺癌及BRCA1/2突变卵巢癌中的持久缓解值得在随机临床试验中进一步研究。
- 原文强调未来免疫检查点抑制剂与PARP抑制剂联合研究需前瞻性选择患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination. OBJECTIVE: To investigate responses associated with the combination of avelumab and talazoparib in different tumor types and/or molecular subtypes. DESIGN, SETTING, AND PARTICIPANTS: In this phase 1b and 2 basket nonrandomized controlled trial, patients with advanced solid tumors were enrolled in the following cohorts: non-small cell lung cancer (NSCLC); DNA damage response (DDR)-positive NSCLC; triple-negative breast cancer (TNBC); hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2)-negative, DDR-positive breast cancer; recurrent, platinum-sensitive ovarian cancer (OC); recurrent, platinum-sensitive, BRCA1/2-altered OC; urothelial cancer; metastatic castration-resistant prostate cancer (mCRPC); DDR-positive mCRPC; and BRCA1/2- or ATM-altered solid tumors. Data were analyzed between June 17, 2021, and August 6, 2021. INTERVENTIONS: All patients in phases 1b and 2 received avelumab plus talazoparib. MAIN OUTCOMES AND MEASURES: The phase 1b primary end point was dose-limiting toxic effects. The phase 2 primary end point was objective response, measured as objective response rate (ORR). Secondary end points included safety, time to response, duration of response (DOR), progression-free survival, time to prostate-specific antigen progression and PSA response of 50% or greater (for mCRPC), cancer antigen 125 response (for OC), pharmacokinetics, immunogenicity, and biomarkers. RESULTS: A total of 223 patients (mean [SD] age, 63.2 [11.0] years; 117 [52.5%] men) were treated, including 12 patients in phase 1b and 211 patients in phase 2. The recommended phase 2 dose was avelumab 800 mg every 2 weeks plus talazoparib 1 mg once daily. In phase 2, the ORR was 18.2% (95% CI, 5.2%-40.3%) in patients with TNBC; 34.8% (95% CI, 16.4%-57.3%) in patients with HR-positive, ERBB2-negative, and DDR-positive BC; and 63.6% (95% CI, 30.8%-89.1%) in patients with platinum-sensitive, BRCA1/2-altered OC. Responses occurred more frequently in patients with BRCA1/2-altered tumors. Durable responses were observed in patients with TNBC (median [range] DOR, 11.1 [3.4-20.4] months); HR-positive, ERBB2-negative, and DDR-positive BC (median [range] DOR, 15.7 [3.9 to ≥20.6] months); and BRCA1/2-altered OC (median DOR not reached; range, 5.6 to ≥18.4 months). The most common grade 3 or greater treatment-related adverse events were anemia (75 patients [33.6%]), thrombocytopenia (48 patients [21.5%]), and neutropenia (31 patients [13.9%]). CONCLUSIONS AND RELEVANCE: This nonrandomized controlled trial found that ORRs for avelumab plus talazoparib were comparable with those with PARP inhibitor or ICI monotherapy. Prolonged DOR in patients with TNBC; HR-positive, ERBB2-negative, and DDR-positive BC; and BRCA1/2-altered OC warrant further investigation in randomized clinical trials. These data highlight the importance of prospective patient selection in future studies of ICI and PARP-inhibitor combinations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03330405.
引用
- Yap TA, Bardia A, Dvorkin M, et al. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2023. PMID: 36394849. doi:10.1001/jamaoncol.2022.5228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。